| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/27/2001 | WO2000061537A3 Pharmaceutical compounds |
| 09/27/2001 | WO2000059489A8 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 09/27/2001 | WO2000057837A8 Compositions and methods for effecting the levels of cholesterol |
| 09/27/2001 | WO2000046386A9 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| 09/27/2001 | WO2000033830A9 An animal model and compounds identified via this model for treatment of chronic pain |
| 09/27/2001 | WO2000012047A3 Enhancement of return to independent living status with a growth hormone secretagogue |
| 09/27/2001 | US20010025113 Nutrients, foods, drugs |
| 09/27/2001 | US20010025108 Thrombosis diseases |
| 09/27/2001 | US20010025107 S-lansoprazole compositions and methods |
| 09/27/2001 | US20010025106 Antiallergens, bronchodilator |
| 09/27/2001 | US20010025104 Amination of clavulanic acid |
| 09/27/2001 | US20010025097 Somatostatins and methods |
| 09/27/2001 | US20010025059 Use of bioflavonoid comprising quercetin, bromelin and papain for reducing symptomatic effects of chronic prostatis |
| 09/27/2001 | US20010025058 Therapy for fungus infections |
| 09/27/2001 | US20010025057 Containing nitric oxide donar containing nitroglycerin, glycol dinitrate, isopropyl nitrate, glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, butane-1,2,4-triol-trinitrate, erythrityl teteranitrate, pentaerithrityl tetetranitrate etc. |
| 09/27/2001 | US20010025056 A formulation for reducing/preventing glycation of proteins of skin and/or nails consists of 3,3,5,5-tetrahydroxystilbene compound or o-alky or o-acycl derivatives |
| 09/27/2001 | US20010025055 New guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions |
| 09/27/2001 | US20010025054 Mono or dinitro substituted phenyl-alkylene-amide-alkylene-amino-alkyelene-aryl or heteroaryl derivatives, useful for prophylaxis and/or treatment of arrhythmia and ischaemic rhythm disorders |
| 09/27/2001 | US20010025053 Administration, to a human or non-human mammal, of an effective amount of nitric oxide synthase inhibitor selected from aminoguanidine, N-methylarginine or other derivatives of arginine for prophylactic treatment of type II diabetes |
| 09/27/2001 | US20010025052 Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same |
| 09/27/2001 | US20010025051 Administering to a breast cancer patient an effective amount of hydroxy containing bicyclic aromatic or heteroaromatic derivatives |
| 09/27/2001 | US20010025048 Methods of use of antimicrobial compounds against pathogenic mycoplasma bacteria |
| 09/27/2001 | US20010025046 A stabilized self-emulsifying system, comprising a o-(chloroacetylcarbamoyl)fumigillol drug, a carrier which is an oily constituent, a surfactant and a stabilizer; angiogenesis inhibitor |
| 09/27/2001 | US20010025044 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli |
| 09/27/2001 | US20010025042 A fused nitrogen containing heterocyclic compound useful for treating psychiatric and neurological disorders, anxiety, post-traumatic stress, supranuclear palsy, feeding, immunological, cardiovascular and hypersensitivity disorders |
| 09/27/2001 | US20010025041 Amidino protease inhibitors |
| 09/27/2001 | US20010025040 Useful for treating allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis; nonsedating antihistamines or salts, leukotriene D4 antagonist or 5-lipoxygenase inhibitor or FLAP protein antagonist |
| 09/27/2001 | US20010025039 Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity |
| 09/27/2001 | US20010025038 Administering to the mammal an effective amount of a D1/D5 (dopamine) antagonist or a D1/D5 partial agonist for reducing cravings of food or an addictive substance |
| 09/27/2001 | US20010025036 Modifying the structure of a 1alpha-hydroxylated vitamin D compound to increase its in vivo activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents 1alphahydroxy in axial orientation |
| 09/27/2001 | US20010025035 Water soluble prodrugs of hindered alcohols |
| 09/27/2001 | US20010025034 Administering to the indivisual suffering from disorders characterized by elevated levels of basic fibroblast growth factor a curcuminoid to inhibit the basic fibroblast growth factor |
| 09/27/2001 | US20010025033 Uracil substituted at 5-position by C2-4 alkynyl used as inactivator of uracil reductase enzyme |
| 09/27/2001 | US20010025032 Administering mixture of nucleosides; anticancer agent |
| 09/27/2001 | US20010025030 cDNA for human methylenetetrahydrofolate reductase and uses thereof |
| 09/27/2001 | US20010025029 Novel stromelysin inhibitors |
| 09/27/2001 | US20010025028 Methods of inhibiting bone resorption |
| 09/27/2001 | US20010025023 Inhibition of beta cell degeneration |
| 09/27/2001 | US20010024824 Stem cells and their use in transplantation |
| 09/27/2001 | US20010024817 Viral nucleotide sequences |
| 09/27/2001 | US20010024809 Administering phenylpropanoid derivative as nutrient or therapy; cultured from Ajuga plant under aerobic conditions; free radical scavengers |
| 09/27/2001 | US20010024795 Detecting very low concentration of a molecule by contacting a sample with a multispecific molecule capable of binding the molecule to be detected forming a complex, which is then bound by another molecule linked by a polymer to many signals |
| 09/27/2001 | US20010024781 Substituted-2,3,4,10-tetrahydrobenzo(g)pteridin-2,4-diones; decontamination of blood, protein and blood products as well as other fluids such as juices, and surfaces of food, carcasses, bathing surfaces |
| 09/27/2001 | US20010024666 Composition for and method of reducing low density lipoprotein cholesterol concentration |
| 09/27/2001 | US20010024659 Controlled release metformin formulations |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | US20010024637 Novel compositions for use in embolizing blood vessels |
| 09/27/2001 | DE10014645A1 New amidino-aryl substituted biphenyl derivatives and analogs as Factor Xa inhibitors, are useful for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy or angina pectoris |
| 09/27/2001 | DE10014631A1 Treating or preventing UV-induced immunosuppression, using ectoine or its derivatives, is useful in topical care or make-up cosmetic compositions for maintaining the barrier effect of the skin |
| 09/27/2001 | DE10013715A1 New aryl-guanidines with side-chains comprising hydrogen bond donor and acceptor groups, are selective urokinase plasminogen activator inhibitors useful for treating tumors or tumor metastasis |
| 09/27/2001 | DE10013712A1 Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung Nicotine salts with improved taste, process for their preparation and their use |
| 09/27/2001 | DE10012401A1 New arylsulfonyl-substituted benzimidazolone or hydantoin compounds, as insulin secretion promoters are useful for treating diabetes mellitus or investigating B-cell function |
| 09/27/2001 | DE10012151A1 Aerosol inhalant containing vitamin A compound in liposomes based on phosphatidylcholine, useful for treatment of tracheo-bronchial illnesses, especially chronic obstructive pulmonary disease |
| 09/27/2001 | DE10012120A1 New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
| 09/27/2001 | DE10010612A1 Treatment of erectile dysfunction without inducing circulatory side-effects, using penis-specific phosphodiesterase V inhibitors, preferably benzo (4,5) thieno (2,3-d) pyrimidine derivatives |
| 09/27/2001 | CA2409643A1 Improvements in and relating to digestive/laxative compositions |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2404275A1 Cosmetic use of hop and ornithine |
| 09/27/2001 | CA2404260A1 Identification of essential genes in prokaryotes |
| 09/27/2001 | CA2404236A1 Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| 09/27/2001 | CA2404226A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 09/27/2001 | CA2404216A1 Novel polypeptides, and nucleic acids encoding the same |
| 09/27/2001 | CA2404206A1 Protease inhibitors |
| 09/27/2001 | CA2404131A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| 09/27/2001 | CA2404112A1 Sustained release delivery systems for solutes |
| 09/27/2001 | CA2404076A1 Heterocyclic side chain containing metalloprotease inhibitors |
| 09/27/2001 | CA2404064A1 Stabilized dry powder formulations |
| 09/27/2001 | CA2404002A1 Inhibitors of histone deacetylase |
| 09/27/2001 | CA2403828A1 Inhibitors of p38 |
| 09/27/2001 | CA2403823A1 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 09/27/2001 | CA2403818A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 09/27/2001 | CA2403815A1 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | CA2403809A1 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 09/27/2001 | CA2403808A1 Thiepino [3,2-b] dihydropyridines and related compositions and methods |
| 09/27/2001 | CA2403805A1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 09/27/2001 | CA2403778A1 Carbocyclic side chain containing metalloprotease inhibitors |
| 09/27/2001 | CA2403714A1 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries |
| 09/27/2001 | CA2403707A1 Diphenyl ketoaldehyde derivatives with anti-hiv activity |
| 09/27/2001 | CA2403684A1 Therapeutic anti-melanoma compounds |
| 09/27/2001 | CA2403669A1 Methods and reagents for regulation of cellular responses in biological systems |
| 09/27/2001 | CA2403631A1 Spiropiperidine derivatives as melanocortin receptor agonists |
| 09/27/2001 | CA2403558A1 Thrombin inhibitors |
| 09/27/2001 | CA2403548A1 Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones |
| 09/27/2001 | CA2403533A1 Methods and systems for enhancing fluid flow through an obstructed vascular site |
| 09/27/2001 | CA2403461A1 Sponge antitumor compounds |
| 09/27/2001 | CA2403444A1 Restenosis treatment |
| 09/27/2001 | CA2403382A1 Novel processes for preparing torsemide intermediate |
| 09/27/2001 | CA2403075A1 Mono- and disaccharides for the treatment of nitric oxide related disorders |
| 09/27/2001 | CA2402836A1 Process for preparing crystalline form i of cabergoline |
| 09/27/2001 | CA2402834A1 Brca-1 regulators and methods of use |
| 09/27/2001 | CA2402655A1 Process for the preparation of midazolam |
| 09/27/2001 | CA2402611A1 Bactericidal preparation |
| 09/27/2001 | CA2402572A1 3-oxy-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadazine-1,1-dioxide derivatives having diuretic and/or natriuretic activity |
| 09/27/2001 | CA2402414A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2402403A1 6-hydroxy-indazole derivatives for treating glaucoma |
| 09/27/2001 | CA2401984A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401969A1 5ht2 agonists for controlling iop and treating glaucoma |
| 09/27/2001 | CA2401959A1 5-hydroxy indazole derivatives for treating glaucoma |
| 09/27/2001 | CA2401908A1 Amorphous torasemide modification |
| 09/27/2001 | CA2401887A1 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |